Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda
pembrolizumab · Merck Sharp & Dohme
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with recurrent or metastatic cutaneous squamous cell carcinoma that could not be cured with surgery or radiation.
LAMPGEN ANALYSIS
Why it matters
Added systemic immunotherapy when local curative treatment was unavailable.
What research teams should watch
Document multidisciplinary assessment of surgery and radiotherapy and standardize imaging or lesion photography.
PRIMARY RECORDS